LMR Partners’s Harmony Biosciences HRMY Stock Holding History

LMR Partners’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,000	Closed	-$3.83M	–	1200
2021 Q3	$3.83M	Buy	+100,000	New	+$3.22M	0.04%	316

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

LMR Partners's HRMY Position: Q4 2021 in Review

LMR Partners sold out of Harmony Biosciences (HRMY) in Q4 2021, closing a stake of 100,000 shares — an estimated $3.83M sold.

LMR Partners first reported a position in HRMY in Q3 2021 and held it in 1 quarter. The position peaked at $3.83M in Q3 2021. 147 funds tracked by Wall St. Rank hold HRMY as of Q4 2021.

LMR Partners reported no remaining Harmony Biosciences position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 100,000 Harmony Biosciences shares in Q4 2021, an estimated $3.83M.
LMR Partners first reported a position in Harmony Biosciences in Q3 2021 and held it in 1 quarter.
LMR Partners's Harmony Biosciences position peaked at $3.83M in Q3 2021.
147 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.